ClinicalTrials.gg
RecruitingNCT05890677LYMPHUpdated Oct 22, 2026

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

An interventional study of Surgical Intervention and Conservative Complex Physical Decongestion Therapy in Lymphedema, Breast Cancer, sponsored by University Hospital, Basel, Switzerland. Recruiting at 36 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Oct 22, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)

Read the detailed description

To date, conservative complex physical decongestion therapy (CDT) is the gold standard for BCRL (breast cancer related lymphedema) and includes manual lymphatic drainage, local compression with bandages and garments, physical exercises and meticulous skin care. It is, however, too often ineffective to prevent stage progression in curing BCRL and purely symptomatic. Lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) are two surgical techniques that, in contrast to CDT, are able to actually address the underlying causes and eventually restore the lymphatic drainage. LVA achieves this by creating numerous bypasses between lymphatic vessels and venules allowing the drainage of excessive fluid within the subcutaneous tissues into the venous system, while VLNT usually brings functioning lymph nodes to an area devoid of lymph nodes or with dysfunctional lymph nodes, thus enabling the spontaneous development of new lymphatic pathways. Both techniques have shown very promising results with low complication rates and improved Quality of Life (QoL) for the patients. However, no multicentric randomized controlled trial (RCT) has yet prospectively evaluated the superiority of these surgical techniques over CDT alone, limiting patient's access to most effective treatment available. Requests for cost reimbursement must still be submitted to insurance companies in most countries and are often rejected, thus delaying surgical treatment and resulting in prolonged suffering of affected patients. This is untenable seeing as affected patients suffer from a heavy physical, psychological and financial burden. This pragmatic, randomized, multicenter trial aims to establish a solid scientific basis assessing the superiority of surgical treatment over CDT alone.

02

Conditions studied

  • Lymphedema, Breast Cancer

Keywords

  • lymphatic surgery
  • breast cancer related lymphedema
  • sentinel lymph node biopsy
  • axillary lymph node dissection
  • manual lymphatic drainage
  • conservative complex physical decongestion therapy
03

In context

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.

This study's planned enrollment of 280 is above the median of 48 across 97 interventional studies indexed under Breast Cancer Lymphedema.

Browse Breast Cancer Lymphedema studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Patients ≥ 18 years of age.
  • Former diagnosis of breast cancer.
  • Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.
  • Minimum of 3 months Conservative Complex Physical Decongestion Therapy.
  • Ability to complete the QoL questionnaires.
  • Willingness to undergo surgery.

Exclusion criteria

Exclusion Criteria:

  • No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented).
  • Primary congenital Lymphedema or non-BCRL.
  • Previous surgical BCRL treatment on the side intended for intervention.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Group A : Surgical Group

    According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which resembles the flexibility in usual care. The key aspects of the preoperative workup and the surgery including the number of LVAs (Lymphovenous Anastomosis), harvesting of lymph nodes ("donor site"), time of surgery, and practical details will be registered.

    Procedure: Surgical Intervention

  • Active comparator
    Group B: Conservative Complex Physical Decongestion Therapy (control group)

    CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when lymphatic drainage is performed and time and class of compressive garments are used will be documented. CDT incorporates two stages of treatment. The first treatment phase (intensive phase) entails skincare, MLD (manual lymphatic drainage), exercises aimed at improvement of mobility/range of motion in the shoulder, elbow or wrist joints, and compression therapy through bandaging. Most patients undergo this phase shortly after the diagnosis of LE. CDT in the second phase (maintenance phase) aims to maintain the achieved limb volume/ circumference reduction through compression with therapeutic elastic compression garment for the arm. Skincare, mobility exercises and MLD is continued in this phase if needed

    Procedure: Conservative Complex Physical Decongestion Therapy

Interventions

  • ProcedureSurgical Intervention

    LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.

  • ProcedureConservative Complex Physical Decongestion Therapy

    Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.

06

What researchers measure

Primary outcomes

  1. Change in Quality of Life Questionnaire (Lymph-ICF-UL)

    The LYMPH-ICF-UL-Questionnaire (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema) is a widely used, rigorously developed, and validated patient-reported outcome (PRO) instrument for chronic breast cancer-related lymphedema. It assesses the impairments in function, activity limitations and participation restrictions of patients with upper limb lymphedema (LE). Consisting of 29 items (questions) across five different domains, each item is scored on a VAS (visual analog scale) ranging from 0 to 10. The total score on the LYMPH-ICF is equal to the sum of the item scores divided by the total number of answered items. A higher score on the Lymph-ICF indicates a greater impact on the functioning in daily life related to upper limb LE. This questionnaire helps determine if lymphatic surgery improves quality of life and patient satisfaction compared to conservative therapy.

    Time frame: two time assessment at baseline and 15 month after randomization

Secondary outcomes

  1. Change in Quality of Life Questionnaire (Lymph-ICF-UL)

    The LYMPH-ICF-UL-Questionnaire (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema) is a widely used, rigorously developed, and validated patient-reported outcome (PRO) instrument for chronic breast cancer-related lymphedema. It assesses the impairments in function, activity limitations and participation restrictions of patients with upper limb lymphedema (LE). Consisting of 29 items (questions) across five different domains, each item is scored on a VAS (visual analog scale) ranging from 0 to 10. The total score on the LYMPH-ICF is equal to the sum of the item scores divided by the total number of answered items. A higher score on the Lymph-ICF indicates a greater impact on the functioning in daily life related to upper limb LE. This questionnaire helps determine if lymphatic surgery improves quality of life and patient satisfaction compared to conservative therapy.

    Time frame: 13 time assessment up to 10 years after randomization

  2. Change in Quality of Life Questionnaire (LYMPH-Q)

    The Lymph-Q Upper Extremity Module is a new PROM (patient-reported outcome measure) developed to assess patient reported outcomes of BCRL in a concept-driven approach. The complete questionnaire contains 68 questions covering the patient-relevant topics Health-related quality of life (arm appearance, arm function, arm symptoms, psychological), experience of care (information), and treatment (arm sleeve). The questionnaire is used to determine whether lymphatic surgery provides better quality of life and patient satisfaction compared to conservative therapy.

    Time frame: 15 time assessment up to 10 years after randomization

  3. Change in Quality of Life Questionnaire (EuroQol EQ-5D-5L)

    The 5-level EQ-5D version (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions (5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems) resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension can be combined into a 5-digit number that describes the patient's health state. The questionnaire is used to determine whether lymphatic surgery provides better quality of life and patient satisfaction compared to conservative therapy.

    Time frame: 15 time assessment up to 10 years after randomization

  4. Change in Pain score (visual analog scale)

    The pain score consists of a VAS (visual analog scale) ranging from 0 (i.e. no pain) to 10 (i.e. worst pain). The VAS was published by the Yale University. It is used to determine whether lymphatic surgery provides better quality of life and patient satisfaction compared to conservative therapy.

    Time frame: 7 time assessment up to 2 years after randomization

  5. Assessment of (serious) adverse events

    Safety is assessed via a rigorous and detailed examination of (serious) adverse events.

    Time frame: 7 time assessment up to 2 years after randomization

  6. Assessment of surgical complications

    For the surgery group only, safety is assessed via a rigorous and detailed examination of complications of surgery. Grading is according to the modified classification of Clavien-Dindo, categorizing them into five levels ranging from minor deviations to life-threatening events. The assessment will cover both surgical stages in case of two-staged lymphedema (LE) surgery.

    Time frame: 7 time assessment up to 2 years after randomization

  7. Assessment of lymphangitic events (erysipelas)

    The frequency of lymphangitic events (erysipelas) is closely monitored. Lymphangitic events are defined as skin infections at the lymphedema site(s) which can be treated with oral or intravenous antibiotics. The type of antibiotic given, the application form, type of hospital stay and necessity of a surgery will be assessed.

    Time frame: 7 time assessment up to 2 years after randomization

  8. Assessment of arm volume

    Arm volume is determined by measuring the circumference of each arm at 10 cm intervals from the wrist to the axilla. The volume of each arm segment is calculated using a truncated cone model, and percentage edema volume is derived from the volume difference between the affected and unaffected arms. Both relative (relative to the unaffected arm) and absolute (volume reduction of the affected arm at the next measurement) volume change are calculated, corrected for BMI and differences between dominant and non-dominant arms.

    Time frame: 15 time assessment up to 10 years after randomization

  9. Assessment of the frequency of lymphatic drainage

    The frequency of lymphatic drainage before the start of the study and between the study's follow-up visits is assessed.

    Time frame: 15 time assessment up to 10 years after randomization

  10. Assessment of the burden on patients

    To assess the burden on patients, information regarding the total number of operative procedures, length of hospital stays, number of outpatient visits, and absence from work within two years after randomization and during the extended follow-up is collected.

    Time frame: 9 time assessment up to 10 years after randomization

  11. Assessment of the economics (for Switzerland)

    To perform an economic evaluation, information regarding the condition-related medical resource use, healthcare costs, indirect costs, productivity losses, and incremental cost-effectiveness (quality-adjusted life-years) is collected. The information is based on the responses to the EQ-5D-5L questionnaire, the questions asked under burden on patients, and on other medical resource information recorded in the trial primarily for clinical purposes, at the respective visits. In addition, direct extraction of breast cancer-related lymphedema-related in- and outpatient costs, and corresponding key resource use parameters, are collected from the hospital administration systems of the participating Swiss sites, once at the 2 year follow-up visit .

    Time frame: 9 time assessment up to 10 years after randomization

07

Study locations

33 of 36 sites recruiting
08

References and documents

Publications

  • Kappos EA, Haas Y, Schulz A, Peters F, Savanthrapadian S, Stoffel J, Katapodi MC, Mucklow R, Kaiser B, Haumer A, Etter S, Cattaneo M, Staub D, Ribi K, Shaw J, Handschin TM, Eisenhardt S, Visconti G, Franceschini G, Scardina L, Longo B, Vetter M, Zaman K, Plock JA, Scaglioni M, Gonzalez EG, Quildrian SD, Felmerer G, Mehrara BJ, Ayala JM, Pons G, Kalbermatten DF, Sacks JM, Halle M, Muntean MV, Taylor EM, Mani M, Jung FJ, di Summa PG, Demiri E, Dionyssiou D, Groth AK, Heine N, Vorstenborsch J, Isaac KV, Qiu SS, Engels PE, Serre A, Eberhardt AL, Ebner S, Schwenkglenks M, Stoel Y, Leo C, Horch RE, Blondeel P, Behr B, Kneser U, Prantl L, Boll DT, Granziera C, Hemkens L, Lindenblatt N, Haug M, Schaefer DJ, Hirche C, Pusic AL, Seidenstuecker K, Harder Y, Weber W. The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema - study protocol of a pragmatic randomised international multicentre superiority trial. BMJ Open. 2025 Feb 17;15(2):e090662. doi: 10.1136/bmjopen-2024-090662. PubMed 39961719 ↗

Individual participant data

Plan to share: Yes — Metadata describing the type, size and content of the datasets will be shared along with the study protocol and case report forms on public repositories following FAIR (Findability, Accessibility, Interoperability and Reuse) principles. The DKF of the University of Basel will act as an independent Data Access Committee, storing the data at time of publication on secure servers, maintained and backed-up by the IT-department of the University Hospital Basel. Researchers can request data reuse by submitting a project synopsis via dkf.unibas.ch/contact. Study results will be published in peer-reviewed journals following the Consolidated Standards of Reporting Trials (CONSORT) standards for randomized controlled trials (RCTs) and good publication practice, regardless of outcomes. Authorship for future publications will be based on contributions. An annual safety report is submitted to the local Ethics Committee by the Sponsor-Investigator according to national regulations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2027, 50 months after the start.

Of 66 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 50 months is above that.

Counting every sponsor, half of 69 studies reached it within 18 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jun 6, 2023
StartActual
Jul 14, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Jun 2036
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 5 sites changed recruiting status (3 now recruiting, 2 now withdrawn)
Show 5 sites
  • Yale School of Medicine · New Haven, United StatesNot yet recruiting→Withdrawn
  • University Clinics St.Pölten · Sankt Pölten, AustriaNot yet recruiting→Recruiting
  • Krankenhaus Göttlicher Heiland GmbH · Vienna, AustriaNot yet recruiting→Recruiting
  • Hospital Erasto Gaertner · Paraná, BrazilNot yet recruiting→Withdrawn
  • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, TaiwanNot yet recruiting→Recruiting
Show site
  • Mayo Clinic · Rochester, United States
Show 1 removed
  • Mayo Clinic · Rochester, United States
Oct 22, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Yale School of Medicine · New Haven, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Hospital Erasto Gaertner · Paraná, BrazilContact removed a•••@gmail.com · •••3300
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed. 5 sites changed recruiting status (3 now recruiting, 2 now withdrawn)
    Show 5 sites
    • Yale School of Medicine · New Haven, United StatesNot yet recruiting→Withdrawn
    • University Clinics St.Pölten · Sankt Pölten, AustriaNot yet recruiting→Recruiting
    • Krankenhaus Göttlicher Heiland GmbH · Vienna, AustriaNot yet recruiting→Recruiting
    • Hospital Erasto Gaertner · Paraná, BrazilNot yet recruiting→Withdrawn
    • Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, TaiwanNot yet recruiting→Recruiting
    Show site
    • Mayo Clinic · Rochester, United States
    Show 1 removed
    • Mayo Clinic · Rochester, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Yale School of Medicine · New Haven, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Hospital Erasto Gaertner · Paraná, BrazilContact removed a•••@gmail.com · •••3300
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05890677
Collaborators
Swiss National Science Foundation, Rising Tide Foundation, Krebsforschung Schweiz, Bern, Switzerland
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Jul 14, 2023
Primary completion
Sep 2027 (estimated)
Completion
Jun 2036 (estimated)
Last update
Oct 22, 2026

Study contacts

Elisabeth Kappos, Prof. Dr.
Contact
elisabeth.kappos@usb.ch
+41 61 328 62 54
Elisabeth Kappos, Prof. Dr.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion